Breast cancer is one of the most fatal cancer witnessed in women and is the second leading cause of death. It refers to cancer developed in breast tissues. It is caused by genetic mutation in the DNA of breast cancer cells. These are mainly of three types - Human Epidermal Growth Factor Receptor 2 (HER2), Hormone Receptor (HR)-positive and Triple negative breast cancer (TNBC). HR-positive type is the most common type of breast cancer accounting for around three-fourth of total cases. Diagnosis of breast cancer is done by imaging tests such as mammography, followed by biopsy in certain cases. Treatment of breast cancer is dependent upon various factors such as type of breast cancer, stage of the cancer, sensitivity to hormones, patient’s age, etc.
Growth of global breast cancer therapeutics market is attributed to increasing prevalence of breast cancer, ageing population, rapid changes in lifestyle and increasing public awareness. However, the faces several challenges due to various factors such as patent expiration of blockbuster drugs, stringent regulations, lack of awareness in LICs and high prices of therapies.
The report “Global Breast Cancer Therapeutics Market [(By Drug Type - HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors; By Region – North America (The US), Europe (Germany) & Asia Pacific (Japan)] Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global breast cancer market with market segmentation done across major drug types such as HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors. Future forecasts of DNA vaccine market overall and across various regional markets has been provided in the report till 2025. Furthermore, major industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global breast cancer market include F. Hoffman-La Roche AG, Novartis AG, Eli Lilly and Company, Pfizer Inc., AstraZeneca PLC, among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global breast cancer market.
Breast cancer therapeutics market has witnessed advent of innovative novel therapies such as combination of PARP inhibitors and CDK inhibitors. Advent of personalized breast cancer therapies is also expected to emerge as a game-changer in the industry.
The report “Global Breast Cancer Therapeutics Market [(By Drug Type - HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors; By Region – North America (The US), Europe (Germany) & Asia Pacific (Japan)] Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global breast cancer therapeutics market overall as well as across various geographies. Regional analysis is done across major markets in North America, Europe and Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global breast cancer therapeutics market.
The report has been segmented as following:-
Geographical Coverage
• North America
• Europe
• Asia Pacific
Key Vendors
1. F. Hoffman-La Roche AG
2. Novartis AG
3. Eli Lilly and Company
4. Pfizer Inc.
5. AstraZeneca PLC
1. Executive Summary
2. Research Methodology
3. Breast Cancer
3.1 Overview
3.1.1 Causes
3.1.2 Symptoms
3.1.3 Stages
3.2 Types
3.2.1 Hormone receptor (HR)-positive
3.2.2 Human epidermal growth factor receptor 2 (HER2)-positive
3.2.3 Triple negative breast cancer (TNBC)
3.3 Diagnosis & Treatment
3.3.1 Diagnosis
3.3.2 Treatment
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Stage
4.2.2 Market Share by Type
4.2.3 Market Share by Region
5. Market Segmentation – Drug Type
5.1 HER2 Inhibitors
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 CDK4/6 Inhibitors
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
5.3 Aromatase Inhibitors
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Drug Types
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 Germany
6.2.2.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 Market by Nations
6.3.3 Japan
6.3.3.1 Market Sizing (Actual & Forecasted)
6.3.3.2 Market Share by Drugs
7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Mergers & Acquisitions
7.1.2 Emergence of Novel Therapies
7.1.3 Advent of Personalized & Targeted Therapies
7.2 Growth Drivers
7.2.1 Prevalence of Breast Cancer
7.2.2 Ageing Population
7.2.3 Rapid Changes in Lifestyle
7.2.4 Increasing Public Awareness
7.3 Challenges
7.3.1 Patent Expirations of Blockbuster Drugs
7.3.2 Stringent Regulations
7.3.3 Lack of Awareness in LICs
7.3.4 High Prices of Therapies
8. Competitive Landscape
9. Company Profiles
9.1 F. Hoffman-La Roche AG
9.2 Novartis AG
9.3 Eli Lilly and Company
9.4 Pfizer Inc.
9.5 AstraZeneca PLC
List of Tables
Table 1: Stages of Breast Cancer
Table 2: Aromatase Inhibitors and SERD used in ER+ Breast Cancer
Table 3: Mergers & Acquisition in Breast Cancer Market
Table 4: CDK4/6 Competitive Landscape
Table 5: Global Breast Cancer Drug manufacturers Sales Forecast, FY2018-FY2022E (US$ Billions)
Table 6: Novartis AG Kisqali/ ribociclib Phase III Clinical Trials
Table 7: Eli Lilly and Company Verzenio/ abemaciclib Phase III Clinical Trials
Table 8: Pfizer Inc. Breast Cancer Product Pipeline
Table 9: AstraZeneca PLC Breast Cancer Product Pipeline
List of Figures
Figure 1: Rockville Research – Research Methodology
Figure 2: Hormone Receptor (HR)-positive Diagrammatic Representation
Figure 3: Human Epidermal Growth Factor Receptor 2 (HER2)-positive Diagrammatic Representation
Figure 4: Triple Negative Breast Cancer Diagrammatic Representation
Figure 5: Global Breast Cancer Drugs Market Size by Value, 2017-25E (US$ Billions)
Figure 6: Global Breast Cancer Market Share by Stage (2018)
Figure 7: Global Breast Cancer Market Share by Type (2018)
Figure 8: Global Breast Cancer Drugs Market Share by Region (2018)
Figure 9: Breast Cancer Relative Survival Rates by Nations (2018)
Figure 10: HER2 Inhibitors Action Mechanism
Figure 11: Global Breast Cancer Drugs – HER2 Inhibitors Market Size by Value, FY2016-FY2025E (US$ Billions)
Figure 12: CDK4/6 Inhibitors Action Mechanism
Figure 13: Global Breast Cancer Drugs – CDK4/6 Inhibitors Market Size by Value, FY2016-FY2025E (US$ Billions)
Figure 14: Global Breast Cancer Drugs – Aromatase Inhibitors Market Size by Value, FY2016-FY2025E (US$ Billions)
Figure 15: North America Breast Cancer Drugs Market Size by Value, 2017-25E (US$ Billions)
Figure 16: The US Breast Cancer Drugs Market Size by Value, 2016-25E (US$ Billions)
Figure 17: The US Breast Cancer Market Share by Drug Type (2018)
Figure 18: Europe Breast Cancer Drugs Market Size by Value, 2017-25E (US$ Billions)
Figure 19: Germany Breast Cancer Drugs Market Size by Value, 2017-25E (US$ Millions)
Figure 20: Asia Pacific Breast Cancer Drugs Market Size by Value, 2017-25E (US$ Billions)
Figure 21: Breast Cancer Incidence Rate by Nations Asia Pacific Region, 2018 (per 100,000 people)
Figure 22: Percentage increase in Estimated Number of Breast Cancer Cases in Nations in Asia Pacific, 2012-25 (%)
Figure 23: Japan Breast Cancer Drugs Market Size by Value, 2016-25E (US$ Millions)
Figure 24: Japan Breast Cancer Drugs Market Share by Drug Class (2018E)
Figure 25: Global Breast Cancer Incidence Rate (%), 2018
Figure 26: Global Breast Cancer Incidences with Age
Figure 27: Global Population Percentage Increase by Age, 2010-50 (%)
Figure 28: Number of Oncologists per One million of Population in Selected Nations (2018)
Figure 29: Global Breast Cancer Market Share by Companies (2018)
Figure 30: Global Breast Cancer Drug Type - CDK4/6 Market Share by Companies (2018)
Figure 31: Breast Cancer Drug – CDK4/6 Revenue Forecast by Products, 2015-25E (US$ Millions)
Figure 32: Breast Cancer Drug – Aromatase Inhibitors Historical Market Share 2005-2010
Figure 33: F. Hoffman-La Roche AG Revenue by Business Segment (FY2018)
Figure 34: F. Hoffman-La Roche AG Breast Cancer Product Pipeline
Figure 35: F. Hoffman-La Roche AG Net Sales, FY2013-FY2018 (US$ Billions)
Figure 36: F. Hoffman-La Roche AG Oncology Drug Sales, FY2018 (US$)
Figure 37: Novartis AG Revenue by Business Segment (FY2018)
Figure 38: Novartis AG Net Sales, FY2013-FY2018 (US$ Billions)
Figure 39: Eli Lilly and Company Revenue by Business Segment (FY2018)
Figure 40: Eli Lilly and Company Verzenio Net Sales, FY2018-FY2024E (US$ Million)
Figure 41: Eli Lilly and Company Net Sales, FY2013-FY2018 (US$ Billions)
Figure 42: Pfizer Inc. Revenue by Business Segment (FY2018)
Figure 43: Pfizer Inc. Net Sales, FY2013-FY2018 (US$ Billions)
Figure 44: AstraZeneca PLC Revenue by Business Segment (FY2018)
Figure 45: AstraZeneca PLC Net Sales, FY2013-FY2018 (US$ Billions)
1. F. Hoffman-La Roche AG
2. Novartis AG
3. Eli Lilly and Company
4. Pfizer Inc.
5. AstraZeneca PLC
*If Applicable.
Links
[1] https://www.marketresearchreports.com/countries/usa[2] https://www.marketresearchreports.com/countries/europe[3] https://www.marketresearchreports.com/countries/asia-pacific[4] https://www.marketresearchreports.com/pharma-healthcare[5] https://www.marketresearchreports.com/country-overview-pharma-healthcare[6] https://www.marketresearchreports.com/medical-supplies[7] https://www.marketresearchreports.com/therapeutic[8] https://www.marketresearchreports.com/oncology